Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Iovance Biotherapeutics (IOVA) Operating Margin: 2011-2025

Historic Operating Margin for Iovance Biotherapeutics (IOVA) over the last 4 years, with Sep 2025 value amounting to -140.69%.

  • Iovance Biotherapeutics' Operating Margin rose 1142.00% to -140.69% in Q3 2025 from the same period last year, while for Sep 2025 it was -166.31%, marking a year-over-year increase of 30691.00%. This contributed to the annual value of -240.92% for FY2024, which is 3849407.00% up from last year.
  • Per Iovance Biotherapeutics' latest filing, its Operating Margin stood at -140.69% for Q3 2025, which was up 25.87% from -189.78% recorded in Q2 2025.
  • In the past 5 years, Iovance Biotherapeutics' Operating Margin ranged from a high of -117.48% in Q4 2024 and a low of -46,254.62% during Q2 2023.
  • For the 3-year period, Iovance Biotherapeutics' Operating Margin averaged around -11,428.64%, with its median value being -286.70% (2024).
  • Data for Iovance Biotherapeutics' Operating Margin shows a peak YoY spiked of 4,592,699bps (in 2024) over the last 5 years.
  • Over the past 3 years, Iovance Biotherapeutics' Operating Margin (Quarterly) stood at -25,156.85% in 2023, then soared by 2,503,937bps to -117.48% in 2024, then skyrocketed by 1,142bps to -140.69% in 2025.
  • Its Operating Margin stands at -140.69% for Q3 2025, versus -189.78% for Q2 2025 and -245.76% for Q1 2025.